‘There’s a tremendous spectrum of pathologies that have shown success’

BioXtek CEO Dr Bruce Werber on a new healing paradigm that is going mainstream.

Florida-based biotech BioXtek is pioneering the use of placental tissue-derived products in regenerative medicine. The company’s proprietary BIOPUR process ensures the preservation of essential bioactive properties and has resulted in highly effective regenerative therapies using amniotic fluid and Wharton’s jelly, components that create an optimal anti-inflammatory and anti-fibrotic environment conducive to healing and regeneration.

My take on this: BioXtek’s therapies are available as a variety of membrane patches derived from the human placental sac and tailored to meet different medical needs, from minor wounds to more complex healing requirements. These patches, available in single-layer to quad-layer configurations, leverage the synergy of bioactive molecules to enhance cell proliferation, angiogenesis and tissue regeneration while preventing fibrosis. Additionally, BioXtek is integrating advanced technologies like nanotechnology and AI-driven analytics to further refine the delivery and effectiveness of these therapies, positioning itself as a leader in the field of regenerative medicine that is bringing novel therapeutics to mainstream medicine.

We sat down with BioXtek’s CEO Dr Bruce Werber, DPM, MSc, FACFAS to find out more about innovating regeneration and proving that mechanism of action to the world.

Bruce Werber on therapeutic potential

BioXtek’s major thrust at the moment is using components of the placental sac and the umbilical cord to make patches that come in a variety of sizes and in multiple layers just like the placental sac. These multi-layered membranes are used for most notably wound care. They accelerate the healing of wounds, including diabetic wounds, and third degree burns without leaving any scarring. As well as being used as a covering or a replacement for the pericardium of the heart, these membranes are extremely beneficial in spine surgery and neurosurgery as a replacement for the dura, the covering of the brain and the spine.

A potential secondary use is in orthopedics for tendon repair and for making very small nerve tunnels to help nerves regrow or nerves to grow without scarring. These membranes are very powerful anti-fibroitic, so they stop scarring and they also provide an anti-inflammatory environment, so they’re very, very powerful, just the membranes alone.

Another product, which is undergoing full regulatory approval from FDA, involves Wharton’s jelly and the amniotic fluid, but this will be a therapeutic product. It is not available commercially as of yet as we have to go through what’s called an IND, Investigative New Drug Application, to ultimately achieve a biologics license. So this is a multi-year process. But do note that we have proof of concept studies for this product.

Learn how membrane patches from the human placental sac can be used for various medical needs and more insights, straight from Bruce Werber right HERE.

Thank you for reading! If you enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!